Product Name | Pyr-41 |
Description |
Ubiquitin-Activating Enzyme (E1) Inhibitor |
Purity | >98% |
CAS No. | 418805-02-4 |
Molecular Formula | C17H13N3O7 |
Molecular Weight | 371.3 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in 25 mg/ml DMSO |
Source | Synthetic |
Appearance | Brown Powder |
SMILES | CCOC(=O)C1=CC=C(C=C1)N2C(=O)/C(=CC3=CC=C(O3)[N+](=O)[O-])/C(=O)N2 |
InChI | InChI=1S/C17H13N3O7/c1-2-26-17(23)10-3-5-11(6-4-10)19-16(22)13(15(21)18-19)9-12-7-8-14(27-12)20(24)25/h3-9H,2H2,1H3,(H,18,21)/b13-9- |
InChIKey | ARGIPZKQJGFSGQ-LCYFTJDESA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection S24/25- Avoid contact with skin and eyes Hazard Statements: H302 – May be harmful if swallowed H317 – May cause an allergic skin reaction Precautionary Statements: P280 – Wear protective gloves |
Cite This Product | Pyr41 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-330) |
Alternative Names | Ethyl 4-{(4Z)-4-[(5-nitro-2-furyl)methylene]-3,5-dioxo-1-pyrazolidinyl}benzoate, PYR-41, 4[4-(5-Nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester |
Research Areas | Apoptosis, Cancer |
PubChem ID | 5335621 |
Scientific Background | Pyr-41 inhibits the ubiquitin-activating enzyme E1, thereby modulating the ubiquitination pathway. It is cell permeable and has been used in neuroscience to investigate the role of ubiquitin signaling in neuronal survival, synaptic function, and neurodegenerative disease mechanisms involving protein turnover and stress responses. |
References |
1. Yang Y., et al. (2007) Cancer Res. 67: 9472. 2. Mi L., et al. (2009) J. Biol. Chem. 284: 17039. |
Reviews
There are no reviews yet.